Cancer

Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line

New live-cell imaging data show that Telomir-1 markedly lowers intracellular iron levels at submicromolar concentrations in human keratinocytes, demonstrating potent...

Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025

- Continued low early termination rate among the first 80 study completers suggests Halneuron® and placebotreatmenthave been well tolerated ATLANTA,...

NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

SHELTON, CONNECTICUT / ACCESS Newswire / November 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), today announced that it...

Ontada Presents Framework for Accelerating Clinical Development with Real-World External Control Arms in Phase 2 Trials at ISPOR

The novel framework is designed to help accelerate clinical development through more efficient and informative early-stage trialsBOSTON--(BUSINESS WIRE)--Ontada®, a leader...

The National Children’s Cancer Society (NCCS) Announces New Mission and Vision Statements Reflecting Its Continued Commitment to Families Impacted by Childhood Cancer

The National Children's Cancer Society (NCCS), a leading nonprofit dedicated to supporting children with cancer, their families, and survivors, has...

error: Content is protected !!